Fan 2005.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 72. Age: aripiprazole group, mean = (32 ± 10.2) years; clozapine group: mean = (31 ± 10.8) years. Gender: aripiprazole group: 19 male, 13 female; clozapine group: 20 male, 12 female. History:aripiprazole group: mean = (6.6 ± 3.3) years; clozapine group: mean = (6.4 ± 3.2 ) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 10‐30 mg/day. Mean = (15.68 ± 6.42) mg/day. N = 36. 2. Clozapine: Dose range: 50‐500 mg/day. Mean = (211 ± 31.82) mg/day. N = 36.
Outcomes	Global state: PANSS score decreased rate(recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general pathological subscale score. Adverse effects: central nervous system (somnolence ) extrapyramidal side‐effects, weight gain, postural hypotension, tardive dyskinesia, constipation,endocrine (menstrual disorder), ECG abnormal (Q‐Tc prolongation), change of blood routine.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Although TESS was used to assess adverse effects, no data on score were available. Data on laboratory tests (urine routine, glucose, liver function) and ECG were missing.
Other bias	Low risk	None obvious.